Update on the treatment of small cell lung cancer (SCLC)

Annals of Oncology

Volumn 11, Issue SUPPL. 3, 2000, Pages 101-108

  Ardizzoni, Andrea ^a   Grossi, Francesco ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; IFOSFAMIDE; IRINOTECAN; MARIMASTAT; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; SATRAPLATIN; TAXANE DERIVATIVE; TOPOTECAN; VINCRISTINE;

BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MEGADOSE; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033779248     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1011115713452     Document Type: Conference Paper

References (80)

1. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: A stopped multicentre randomized trial - Medical Research Council Lung Cancer Working Party
2. Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomised comparison with intravenous chemotherapy
3. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology group study
4. Phase II study of taxol in patients (pts) with extensive-stage small cell lung cancer (SCLC): An Eastern Cooperative Oncology Group Study
5. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: A study of the North Central Cancer Treatment Group
6. Phase II study of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer
7. Docetaxel (Taxotere) in extensive stage small cell lung cancer (SCLC): A phase II trial of the southwest oncology group (SWOG)
8. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT)
9. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An eastern cooperative oncology group trial
10. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)
11. Phase II study of oral paltinum drug JM216 as first-line treatment in patients with small-cell lung cancer
12. Paclitaxel, carboplatin and extended schedule etoposide in the treatment of small cell lung carcinoma
13. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma
14. Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy
15. Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer
16. Dose intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung
17. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
18. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
19. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer
20. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating facto support: Results of a British Medical Research Council multicenter randomized trial
21. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients
22. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
23. Reduction of chemotherapy-induced febrile leukopenia by ciprofloxacin and roxithromycin in small cell lung cancer (SCLC) patients: An EORTC phase III study
24. A meta-analysis of thoracic radiotherapy for small cell lung cancer
25. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis
26. The importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer
27. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study
28. Final results of a phase Ill study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (P) and etoposide (E) for limited-stage small cell lung cancer (LD-SCLC): The Japan Clinical Oncology Group (JCOG) study
29. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer
30. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung
31. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of Cancer and Leukemia Group B study 8083
32. Thoracic radiotherapy variables: Influence on local control in small cell lung cancer limited disease
33. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group study
34. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine
35. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer
36. Twice-daily compared with once daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
37. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma
38. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
39. A randomized combined modality trial in small cell carcinoma of the lung-comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation
40. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomized, controlled trial
41. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer - Report to the Medical Research Council by its Lung Cancer Working Party
42. Duration of chemotherapy in small cell lung cancer: A Cancer Research Campaign trial
43. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party
44. Maintenance chemotherapy in limited small cell lung cancer: A randomised controlled clinical trial
45. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: A phase III study of the Eastern Cooperative Oncology Group
46. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: Definitive results of a randomized clinical trial. The 'Petites Cellules' Group
47. Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
48. A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party
49. Phase III trial of maintenance daily oral VP-16 versus no further therapy following induction chemotherapy with VP-16 (V) plus ifosfamide (I) plus cisplatin (P) (VIP) in extensive small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) trial (LUN93-2)
50. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer
51. Natural interferon alfa as maintenance therapy for small cell lung cancer
52. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung
53. Dose-intensive therapy in small cell lung cancer
54. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study
55. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation
56. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer
57. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group
58. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin
59. Second line chemotherapy in small cell lung cancer
60. Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin-resistant small-cell lung cancer
61. A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer
62. Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC)
63. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer
64. Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC)
65. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
66. Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): A phase II study
67. Evaluation of Topotecan (HycamtinTM) in relapsed small cell lung cancer (SCLC). A multicentre phase II study
68. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan
69. Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)
70. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
71. A multicentre randomised phase II study of oral Topotecan versus iv Topotecan for second line therapy in sensitive patients with small cell lung cancer
72. A phase II study of paclitaxel in heavily pretreated patients with small cell lung cancer
73. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule
74. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC
75. Phase II study of vinorelbine (Navelbine)in previously treated small cell lung cancer patients
76. Phase II study of vinorelbine in heavily previously treated small cell lung cancer
77. The activity of gemcitabine in patients with resistant small cell lung cancer (SCLC); a phase II study
78. Teniposide for brain metastases of small-cell lung cancer: A phase II study
79. Chemotherapy for brain metastases of lung cancer: A review
80. Topotecan (Hycamtin) in small cell lung cancer (SCLC) after failure of first line therapy: Multicentre phase II study